Appili Therapeutics Inc (PK) (APLIF)

Shedding of adtx was the best thing to have done. Market over reacting... a good time to buy. I did.

Glad to see the yoke of ADTX has been removed! Now the company can focus.
ADTX was a lousy company to merge or sell to or partner with in any form.
I see it as taking a good early morning dump.

Looks interesting

JUST THE BEGINNING HERE....8C BREAK SENDS THIS BIG TIME

ONLY ONE?

Congratulations you actually got one ticker right out of hundreds. Great Job! LOL

BOOM...BIG VOLME OUT OF THE GATE

DUMMY

FDA!!!!!!

The global metronidazole market was valued at USD 1.5 billion in 2018 and is projected to reach USD 2.2 billion by 2030, growing at a CAGR of 3% during the forecast period from 2021-2030. The market for metronidazole tablets segment accounted for the largest share in 2018 with over 50% share followed by metronidazole injection segment with over 30%. The demand for metronidazole tablets segment will continue to grow due to its high usage in treatment of various diseases such as bacterial vaginosis, trichomoniasis, and amebiasis among others which are expected to drive growth during the forecast period from 2021-2030.

The global Metronidazole market size is estimated to be worth US$ 113 million in 2021 and is forecast to a readjusted size of US$ 109.1 million by 2028 with a CAGR of -0.5% during the forecast period 2022-2030.

Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections. The current tablet form of metronidazole is the only approved oral form on the U.S. market, but its bitter taste and lack of appropriate dosage forms for patients with difficulty swallowing often presents treatment compliance challenges

FDA DECISION NEXT WEEK. LETS HOPE IT HAPPENS!!

Huge wall@04 676,134 shares

Yes but the investment was for the good. Through Appili’s unique approach to drug development, we have created a pipeline containing a deliberate mix of close-to-market opportunities that have the potential to provide near-term value with cutting-edge programs that we believe have the potential to transform how we treat many infectious diseases, addressing significant unmet medical needs in patient care.

This approach allows Appili to seek productive collaborations with industry partners and federal government agencies whose objectives align with ours, while pursuing non-dilutive funding sources specifically earmarked for infectious diseases development programs.

APLIF as of Year ended March of 2022 The company lost 25 million Dollars or .38 cents per share. Then as of Year ending March of 2023 they lost another 9.2 million Dollars or .08 cents per share. You Were Warned! Don't Be Schooled:

https://www.otcmarkets.com/otcapi/company/financial-report/375623/content

APLIF...NEXT BIO DEFENSE BEAST OUT OF HALIFAX...